An Oral Cannabinoid Study Found Bronchial Effects Were Not Shared Equally by THC, CBD and CBN

A 1984 series of controlled oral-cannabinoid experiments found bronchodilator activity with THC-related conditions, but not effective bronchodilation from CBD, CBN or their tested combinations. The historical physiological findings do not establish an asthma treatment.

Experienced smokers received oral compounds

The double-blind experiments examined dose responses, combinations and repeated administration in experienced marijuana smokers. This was not a comparison of smoke inhalation with inhalers. The abstract reported no significant dose-related physiological effects for several tested compounds, while noting a delta-8 condition with bronchial, heart-rate and subjective effects smaller than delta-9 THC's.

A combination could affect one endpoint without another

Adding CBN or CBD to low-dose delta-9 THC did not produce significant bronchodilation but did show interactions in heart rate and reported high. Those results prevent treating an absence of one physiological effect as absence of all drug interaction.

The repeated-dose result was protocol-specific

A 20-day daily-administration comparison did not indicate tolerance or reverse tolerance on the reported outcomes. That finding cannot establish that these compounds never produce tolerance. Dose, prior cannabis experience, route and the particular physiological measure define its scope.

The study distinguishes chemical constituents rather than treating all cannabinoids as one drug. It does not demonstrate sustained respiratory benefit, symptom control or clinical safety for people with airway disease. A measured airway response and an effective treatment are different evidentiary claims.

Related: interpreting cannabis tolerance claims.

Research cited

Gong H; Tashkin DP; Simmons MS; Calvarese B; Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clinical pharmacology and therapeutics (1984). doi:10.1038/clpt.1984.4. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Different Amygdala Findings Varied by Both Subregion and Recording Method

Apparently different cannabinoid effects within the central amygdala could not be assigned solely to anatomy when recording methods differed as well. A paper discussing its medial recordings identified this interpretive limit. The current experiment measured spontaneous transmission Varodayan and colleagues recorded spontaneous and miniature GABAergic currents from the medial subdivision…

Spread the love

Read Article: Different Amygdala Findings Varied by Both Subregion and Recording Method

CB1 and CB2 Antagonists Gave Different Answers for WIN’s Synaptic Effect

A drug capable of activating more than one cannabinoid receptor needs evidence identifying the receptor responsible for a particular effect. A rat amygdala experiment compared CB1 and CB2 antagonism rather than relying only on WIN55,212-2’s drug-class label. The agonist first reduced inhibitory-current frequency Varodayan and colleagues applied WIN to central-amygdala…

Spread the love

Read Article: CB1 and CB2 Antagonists Gave Different Answers for WIN’s Synaptic Effect

A Weaker Direct WIN Response Did Not Eliminate Its Interaction With Alcohol

After chronic alcohol exposure, an experimental cannabinoid agonist had a diminished direct effect on GABA release but still prevented an acute alcohol-related increase. Reduced sensitivity depended on which response was being examined. The direct agonist challenge was attenuated Varodayan and colleagues found that WIN55,212-2 reduced inhibitory-current frequency in alcohol-naive rat…

Spread the love

Read Article: A Weaker Direct WIN Response Did Not Eliminate Its Interaction With Alcohol

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us